PE20161560A1 - Vacuna de pcsk9 - Google Patents

Vacuna de pcsk9

Info

Publication number
PE20161560A1
PE20161560A1 PE2016002242A PE2016002242A PE20161560A1 PE 20161560 A1 PE20161560 A1 PE 20161560A1 PE 2016002242 A PE2016002242 A PE 2016002242A PE 2016002242 A PE2016002242 A PE 2016002242A PE 20161560 A1 PE20161560 A1 PE 20161560A1
Authority
PE
Peru
Prior art keywords
pcsk9
antigenic
seq
amino acid
acid sequence
Prior art date
Application number
PE2016002242A
Other languages
English (en)
Inventor
David Michael Wyatt
Jakir Hussain Ullah
Xiayang Qiu
Brian Gregory Pierce
Brian Robert Champion
Julie Jia Li Hawkins
James Downey Fraser
Michael Dale Eisenbraun
Jr Leonard Gabriel Contillo
James Richard Merson
Original Assignee
Pfizer Vaccines Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Vaccines Llc filed Critical Pfizer Vaccines Llc
Publication of PE20161560A1 publication Critical patent/PE20161560A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/002Protozoa antigens
    • A61K39/005Trypanosoma antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21061Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)

Abstract

Se refiere a una composicion inmunogenica que comprende al menos dos peptidos antigenicos de PCSK9 donde: a) el primer peptido antigenico de PCSK9 consiste en una secuencia de aminoacidos de SEQ ID NO: 182 a 226, 317 y 401 a 403; y b) el segundo peptido antigenico de PCSK9 consiste en una secuencia de aminoacidos de SEQ ID NO: 46-101, 314, 318 y 319; c) un vehiculo inmunogenico tal como CRM197 o VLP de Qbeta; d) un adyuvante tal como alumbre, CpG ODN, QS21 e Iscomatrix. Dicha composicion inmunogenica es util en el tratamiento, alivio o profilaxis de enfermedades asociadas con un nivel elevado de colesterol.
PE2016002242A 2009-09-03 2010-08-23 Vacuna de pcsk9 PE20161560A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23954109P 2009-09-03 2009-09-03

Publications (1)

Publication Number Publication Date
PE20161560A1 true PE20161560A1 (es) 2017-01-11

Family

ID=43413463

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2016002242A PE20161560A1 (es) 2009-09-03 2010-08-23 Vacuna de pcsk9
PE2012000286A PE20121544A1 (es) 2009-09-03 2010-08-23 Vacuna de pcsk9
PE2016002226A PE20161551A1 (es) 2009-09-03 2010-08-23 Vacuna de pcsk9

Family Applications After (2)

Application Number Title Priority Date Filing Date
PE2012000286A PE20121544A1 (es) 2009-09-03 2010-08-23 Vacuna de pcsk9
PE2016002226A PE20161551A1 (es) 2009-09-03 2010-08-23 Vacuna de pcsk9

Country Status (30)

Country Link
US (4) US8889144B2 (es)
EP (3) EP2865752A1 (es)
JP (5) JP2013503623A (es)
KR (3) KR101660578B1 (es)
CN (3) CN104548089B (es)
AR (2) AR078247A1 (es)
AU (1) AU2010290931B2 (es)
BR (1) BR112012004807A2 (es)
CA (2) CA2771770A1 (es)
CO (1) CO6501190A2 (es)
DK (1) DK2473605T3 (es)
ES (1) ES2670576T3 (es)
HK (3) HK1174056A1 (es)
HU (1) HUE037416T2 (es)
IL (2) IL218229A (es)
MX (1) MX2012002639A (es)
MY (1) MY163512A (es)
NO (1) NO2473605T3 (es)
NZ (3) NZ620441A (es)
PE (3) PE20161560A1 (es)
PH (2) PH12016500004A1 (es)
PL (1) PL2473605T3 (es)
PT (1) PT2473605T (es)
RU (2) RU2538162C2 (es)
SA (3) SA110310687B1 (es)
SG (3) SG10201401515YA (es)
SI (1) SI2473605T1 (es)
TR (1) TR201808222T4 (es)
TW (1) TWI400085B (es)
WO (1) WO2011027257A2 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107266582B (zh) 2008-08-29 2021-09-10 口腔健康澳洲私人有限公司 牙龈卟啉单胞菌感染的预防、治疗和诊断
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
PE20110998A1 (es) 2008-12-09 2012-02-10 Coley Pharm Group Inc Oligonucleotidos inmunoestimuladores
GB201005005D0 (en) * 2010-03-25 2010-05-12 Angeletti P Ist Richerche Bio New vaccine
US20140004142A1 (en) * 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
EP2532359A1 (en) 2011-06-10 2012-12-12 Affiris AG CETP fragments
EP2570135B1 (en) 2011-09-13 2016-01-27 Affiris AG PCSK9 Vaccine
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
EP2908854A2 (en) * 2012-10-17 2015-08-26 GlaxoSmithKline Biologicals S.A. Immunogenic composition
US10058630B2 (en) * 2012-10-22 2018-08-28 Concievalve, Llc Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis
WO2014074509A1 (en) * 2012-11-07 2014-05-15 Vacplanta Limted Production of an immunogen using a plant virus
US10117923B2 (en) 2012-11-07 2018-11-06 Vacplanta Limited Production of an immunogen using a plant virus
TWI641382B (zh) * 2013-01-31 2018-11-21 韓美藥品股份有限公司 於包含因子vii之組成物中使病毒失活之方法
CN104043120B (zh) * 2013-03-13 2017-05-31 南京赛威信生物医药有限公司 乙型肝炎疫苗
WO2015123291A1 (en) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Pcsk9 vaccine and methods of using the same
US10004791B2 (en) * 2014-02-28 2018-06-26 Affiris Ag Peptide vaccines against PCSK9
CN104558199B (zh) * 2014-09-05 2018-07-06 成都康弘生物科技有限公司 一种治疗高胆固醇血症的融合蛋白制备及其用途
RU2736642C2 (ru) * 2015-07-20 2020-11-19 Зоэтис Сервисиз Ллс Липосомальные адъювантные композиции
EP3365006A1 (en) 2015-10-19 2018-08-29 Cadila Healthcare Limited New adjuvant and vaccine composition containing the same
WO2017076873A1 (en) * 2015-11-03 2017-05-11 Affiris Ag Method for vaccination against a self-antigen in a human patient
US10980876B2 (en) * 2016-03-25 2021-04-20 Osaka University Conjugate vaccine targeting a disease-causing biological protein
CA3026823A1 (en) * 2016-06-24 2017-12-28 F. Hoffmann-La Roche Ag Compositions and methods for treating cardiovascular disease
CN106822881A (zh) * 2016-12-09 2017-06-13 四川大学 一种针对pcsk9的抗高血脂蛋白疫苗
CA3058567A1 (en) * 2017-04-13 2018-10-18 Cadila Healthcare Limited Novel peptide based pcsk9 vaccine
CN107488215A (zh) * 2017-07-19 2017-12-19 邱志华 人前蛋白转化酶枯草溶菌素9免疫原性肽段及其载体疫苗
US20220380425A1 (en) * 2019-07-04 2022-12-01 Cadila Healthcare Limited Angptl3 based vaccine for the treatment of liver disease
WO2021154947A1 (en) * 2020-01-28 2021-08-05 Ubi Ip Holdings Peptide immunogens targeting pcsk9 and formulations thereof for prevention and treatment of pcsk9-mediated disorders
WO2021176434A1 (en) 2020-03-01 2021-09-10 Valneva Austria Gmbh Cpg-adjuvanted sars-cov-2 virus vaccine
WO2022147373A1 (en) * 2020-12-31 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
WO2023161526A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN
CN117327159A (zh) * 2023-07-31 2024-01-02 杭州纽龙生物科技有限公司 一种蛋白a耐碱突变方法

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773946A (en) 1969-09-02 1973-11-20 Parke Davis & Co Triglyceride-lowering compositions and methods
US3930024A (en) 1969-09-02 1975-12-30 Parke Davis & Co Pharmaceutical compositions and methods
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
WO1980000727A1 (en) 1978-09-29 1980-04-17 Secretary Energy Brit Improvements in and relating to electrical power transmission in fluid wells
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
AU548727B2 (en) 1981-03-12 1986-01-02 Gruppo Lepetit S.P.A. Beta-lactam acetic acid derivatives
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
DE3280400D1 (de) 1981-10-23 1992-06-04 Molecular Biosystems Inc Oligonukleotides heilmittel und dessen herstellungsverfahren.
IL64542A0 (en) 1981-12-15 1982-03-31 Yissum Res Dev Co Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
JPS60136512A (ja) 1983-12-26 1985-07-20 Eisai Co Ltd 脂質代謝改善剤
DE3423166A1 (de) 1984-06-22 1986-01-02 Epis S.A., Zug Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
ES2055785T3 (es) 1989-01-17 1994-09-01 Eniricerche Spa Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas.
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
JPH04506662A (ja) 1989-07-14 1992-11-19 アメリカン・サイアナミド・カンパニー 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー
NZ235315A (en) 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
JP2999579B2 (ja) 1990-07-18 2000-01-17 武田薬品工業株式会社 Dnaおよびその用途
EP0471177B1 (en) 1990-08-13 1995-10-04 American Cyanamid Company Filamentous hemagglutinin of bordetella pertussis as a carrier molecule for conjugate vaccines
WO1992011291A1 (en) 1990-12-20 1992-07-09 Smithkline Beecham Biologicals (S.A.) Vaccines based on hepatitis b surface antigen
DE4202394A1 (de) 1991-04-04 1992-10-08 Teves Gmbh Alfred Schwimmsattel-teilbelagscheibenbremse mit einem bremsengehaeuse aus leichtmetall
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
CA2135052A1 (en) 1992-05-06 1993-11-11 R. John Collier Diphtheria toxin receptor-binding region
ES2143716T3 (es) 1992-06-25 2000-05-16 Smithkline Beecham Biolog Composicion de vacuna que contiene adyuvantes.
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
SG48309A1 (en) 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1167377B2 (en) 1994-07-15 2012-08-08 University of Iowa Research Foundation Immunomodulatory oligonucleotides
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5648387A (en) 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
CN1185811A (zh) 1995-03-31 1998-06-24 H·沃尔夫 依赖于逆转录病毒样颗粒的抗原呈递系统
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
ES2241042T3 (es) 1996-10-11 2005-10-16 The Regents Of The University Of California Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
IL119971A (en) 1997-01-07 2003-02-12 Yissum Res Dev Co Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
CA2281838A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DE69838294T2 (de) 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Verfahren zur Herstellung von Nukleinsäurekonstrukten
PT1003850E (pt) 1997-06-06 2009-08-13 Dynavax Tech Corp Inibidores da actividade de sequências de adn imunoestimulantes
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
IL121165A0 (en) 1997-06-26 1997-11-20 Yissum Res Dev Co Pharmaceutical compositions containing carboxylic acids and derivatives thereof
DE69815692T2 (de) 1997-09-05 2004-04-29 Glaxosmithkline Biologicals S.A. Öl in wasser emulsionen mit saponinen
ID26669A (id) 1998-02-12 2001-01-25 Immune Complex Corp Inti protein-protein hepatitis b yang dimodifikasi secara strategi dan turunan-turunannya
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
CA2323929C (en) 1998-04-03 2004-03-09 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
JP2002511423A (ja) 1998-04-09 2002-04-16 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
DE59806475D1 (de) 1998-09-18 2003-01-09 Pentapharm Ag Basel Urokinase-inhibitoren
WO2000021478A1 (en) 1998-09-28 2000-04-20 Hans Balle Aps Lift, preferably for seats on wheelchairs
US6203837B1 (en) 1998-10-06 2001-03-20 Xcafe' Llc Coffee system
CA2773698C (en) 1998-10-16 2015-05-19 Glaxosmithkline Biologicals S.A. Adjuvant systems comprising an immunostimulant adsorbed to a metallic salt particle and vaccines thereof
AU770802B2 (en) 1998-10-21 2004-03-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Virus-like particles for the induction of autoantibodies
WO2000026385A1 (en) 1998-11-05 2000-05-11 Powderject Vaccines, Inc. Nucleic acid constructs for genetic immunization
CN100534529C (zh) 1998-11-30 2009-09-02 希托斯生物技术股份公司 抗原的有序分子呈递,制备及使用的方法
EP1140157B1 (en) 1998-12-21 2009-02-18 MedImmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
TR200200633T2 (tr) 1998-12-23 2002-06-21 Shire Biochem Inc. Yeni streptococcus antijenleri
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
WO2000048630A1 (en) 1999-02-17 2000-08-24 Csl Limited Immunogenic complexes and methods relating thereto
HU228499B1 (en) 1999-03-19 2013-03-28 Smithkline Beecham Biolog Streptococcus vaccine
BR0009520A (pt) 1999-04-01 2002-06-11 Esperion Therapeutics Inc Composto, método para sintetizar o mesmo, composição, metódos para o tratramento ou prevenção, em um paciente, de doença cardiovascular, dislipidemia, dislipoproteinemia, distúrbio de metabolismo de glucose, doença de alzheimer, sìndrome x ou sìndrome metabólica, septicemia, distúrbio trombótico, distúrbio associado com receptor ativado por proliferador de peroxissoma, obesidade, pancreatite, hipertensão, doença renal, câncer, inflamação, impotência, para reduzir o teor de gordura de carne de gado bovino, e, para reduzir o teor de colesterol de ovos de aves
CA2365914A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
GB9908533D0 (en) 1999-04-14 1999-06-09 Novartis Ag Organic compounds
PT1187629E (pt) 1999-04-19 2005-02-28 Glaxosmithkline Biolog Sa Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
NO309798B1 (no) * 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
CO5200837A1 (es) 1999-09-24 2002-09-27 Smithkline Beecham Corp Vacunas
PL355232A1 (en) 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
EP1220684B2 (en) 1999-09-27 2010-07-14 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
EP1268530B1 (en) 2000-04-07 2006-08-16 University Of Leeds Hepatitis b core antigen fusion proteins
AU2001252458A1 (en) 2000-05-05 2001-11-20 Martin Bachmann Molecular antigen arrays and vaccines
NZ553554A (en) 2000-06-20 2008-11-28 Id Biomedical Corp Streptococcus antigens
ES2260235T3 (es) 2000-06-22 2006-11-01 Ucb Pharma Limited Modificacion del antigeno "core" de la hepatitis b.
EP1304947A1 (en) 2000-07-15 2003-05-02 Lighthouse Display International Limited Shelf edge display fittings
GB0121171D0 (en) * 2001-08-31 2001-10-24 Glaxosmithkline Biolog Sa Vaccine
AUPQ912000A0 (en) 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
US7320793B2 (en) * 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
US20030035806A1 (en) 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
CA2492823A1 (en) 2001-09-14 2003-03-27 Martin F. Bachmann In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
DE60234375D1 (de) * 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
JP4671389B2 (ja) 2001-10-05 2011-04-13 サイトス バイオテクノロジー アーゲー アンジオテンシンペプチド−担体複合体およびその使用
US7262024B2 (en) 2001-12-20 2007-08-28 Id Biomedical Corporation Streptococcus antigens
AU2003213168A1 (en) 2002-02-21 2003-12-19 Apovia, Inc. IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE
GB0209878D0 (en) 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
MXPA05000277A (es) 2002-07-17 2005-03-31 Cytos Biotechnology Ag Configuraciones de antigenos moleculares de usan una particula tipo virus derivada de la proteina de recurimiento ap205.
GB0219524D0 (en) * 2002-08-21 2002-10-02 Queen Mary & Westfield College Therapeutic uses of monoclonal antibodies to the angiotensin-II type-1 receptor
ATE546156T1 (de) 2002-12-10 2012-03-15 Sanofi Pasteur Biologics Co Stabilisierte immunogene chimäre hbc-partikel
DE602004010376T2 (de) 2003-03-13 2008-10-23 Glaxosmithkline Biologicals S.A. Verfahren zur reinigung von bakteriellem cytolysin
EP1471152A1 (en) 2003-04-25 2004-10-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutations in the human PCSK9 gene associated to hypercholesterolemia
JP2008506683A (ja) 2004-07-18 2008-03-06 コーリー ファーマシューティカル グループ, リミテッド 先天免疫応答を誘導するための方法および組成物
NZ553244A (en) 2004-07-18 2009-10-30 Csl Ltd Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
GB0421083D0 (en) 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
ES2553284T5 (es) 2006-02-15 2021-08-31 Rechtsanwalt Thomas Beck Composiciones y procedimientos para formulaciones de oligonucleótidos
CA2652247C (en) * 2006-05-08 2015-11-17 Adaerata, Limited Partnership Chimeric pcsk9 proteins, cells comprising same, and assays using same
US7572618B2 (en) * 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
US20080166785A1 (en) 2006-08-16 2008-07-10 Monica Sala-Schaeffer Polynucleotides allowing the expression and secretion of recombinant HBsAg virus-like particles containing a foreign peptide, their production and use
US8263353B2 (en) * 2007-03-27 2012-09-11 Merck Sharp & Dohme Corp. Method for detecting autoprocessed, secreted PCSK9
AR066042A1 (es) * 2007-04-13 2009-07-22 Novartis Ag Moleculas y metodos para modular la proteina convertasa-subtilisina /quexina tipo 9 (pcsk9)
KR20100045445A (ko) 2007-06-26 2010-05-03 글락소스미스클라인 바이오로지칼즈 에스.에이. 스트렙토코쿠스 뉴모니애 캡슐 다당류 컨쥬게이트를 포함하는 백신
JOP20080381B1 (ar) * 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US8598320B2 (en) * 2007-10-26 2013-12-03 Merck Sharp & Dohme Corp. Anti-PCSK9 and methods for treating lipid and cholesterol disorders
CA2710141A1 (en) * 2007-12-20 2009-07-02 Cytos Biotechnology Ag Ngf conjugates and uses thereof
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
AR070315A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
TWI516501B (zh) * 2008-09-12 2016-01-11 禮納特神經系統科學公司 Pcsk9拮抗劑類
AT507604A1 (de) 2008-11-19 2010-06-15 Affiris Forschungs & Entwicklungs Gmbh Behandlung von atherosklerose
US9501570B2 (en) 2014-07-14 2016-11-22 Verizon Patent And Licensing Inc. Dynamic routing system
US9719791B2 (en) 2014-12-10 2017-08-01 Mapquest, Inc. Computerized systems and methods for providing travel information and/or content to users
WO2017221077A2 (en) 2016-06-23 2017-12-28 Steam Cc Ltd. Method and apparatus for printing on a drink
US10114918B2 (en) 2016-01-27 2018-10-30 Arm Limited Physical placement control for an integrated circuit based on state bounds file

Also Published As

Publication number Publication date
JP5859150B2 (ja) 2016-02-10
BR112012004807A2 (pt) 2017-04-11
PE20161551A1 (es) 2017-01-18
RU2014143531A (ru) 2016-05-20
JP2018039821A (ja) 2018-03-15
EP2473605B1 (en) 2018-04-11
PE20121544A1 (es) 2012-12-02
AR078247A1 (es) 2011-10-26
IL218229A (en) 2017-10-31
SG178447A1 (en) 2012-03-29
US8889144B2 (en) 2014-11-18
EP2473605A2 (en) 2012-07-11
KR20120089451A (ko) 2012-08-10
HK1209619A1 (en) 2016-04-08
IL254600A0 (en) 2017-11-30
HUE037416T2 (hu) 2018-08-28
RU2014143531A3 (es) 2018-06-22
JP2013503623A (ja) 2013-02-04
AR107020A2 (es) 2018-03-14
RU2538162C2 (ru) 2015-01-10
KR101660577B1 (ko) 2016-09-27
TW201113035A (en) 2011-04-16
CN104587462B (zh) 2017-09-26
CO6501190A2 (es) 2012-08-15
JP2017039748A (ja) 2017-02-23
KR20140004263A (ko) 2014-01-10
DK2473605T3 (en) 2018-05-28
CN102612558B (zh) 2015-02-11
AU2010290931B2 (en) 2014-02-06
AU2010290931A1 (en) 2012-03-29
SI2473605T1 (en) 2018-06-29
US20170100467A1 (en) 2017-04-13
US9987341B2 (en) 2018-06-05
CA2771770A1 (en) 2011-03-10
SA114350178B1 (ar) 2017-03-05
ES2670576T3 (es) 2018-05-31
PH12016500004A1 (en) 2016-12-05
JP2015131814A (ja) 2015-07-23
TR201808222T4 (tr) 2018-07-23
SA114350179B1 (ar) 2016-03-01
KR20140007500A (ko) 2014-01-17
CN104587462A (zh) 2015-05-06
PT2473605T (pt) 2018-05-28
NZ599059A (en) 2014-05-30
HK1174056A1 (en) 2013-05-31
US9481875B2 (en) 2016-11-01
PH12016500040A1 (en) 2016-12-05
KR101660578B1 (ko) 2016-09-27
SA110310687B1 (ar) 2014-10-16
CN104548089A (zh) 2015-04-29
RU2012107657A (ru) 2013-10-10
US20180318407A1 (en) 2018-11-08
TWI400085B (zh) 2013-07-01
NZ710626A (en) 2017-03-31
NZ620441A (en) 2015-08-28
SG10201401516XA (en) 2014-10-30
MY163512A (en) 2017-09-15
PL2473605T3 (pl) 2018-08-31
US20150098957A1 (en) 2015-04-09
US20110052621A1 (en) 2011-03-03
WO2011027257A3 (en) 2011-06-30
IL218229A0 (en) 2012-04-30
CN102612558A (zh) 2012-07-25
KR101512053B1 (ko) 2015-04-28
SG10201401515YA (en) 2014-08-28
NO2473605T3 (es) 2018-09-08
HK1208346A1 (en) 2016-03-04
MX2012002639A (es) 2012-03-14
WO2011027257A2 (en) 2011-03-10
CA2846746A1 (en) 2011-03-10
EP3358008A1 (en) 2018-08-08
CN104548089B (zh) 2017-09-26
JP2016106089A (ja) 2016-06-16
EP2865752A1 (en) 2015-04-29

Similar Documents

Publication Publication Date Title
PE20161560A1 (es) Vacuna de pcsk9
PE20100658A1 (es) COMPOSICION INMUNOGENICA QUE COMPRENDE gE VZV Y UN ADYUVANTE QUE CONTIENE QS21, COLESTEROL Y 3D-MPL
ES2563646T3 (es) Composiciones y métodos relacionados con variantes de la proteína A (SpA)
AR125327A2 (es) Composiciones de neisseria meningitidis y métodos de las mismas
PE20110891A1 (es) Vacuna de peptido ch3 de ige
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
ES2673556T3 (es) Vacunas para el VHS-2
NZ604089A (en) Multivalent glycopeptide constructs and uses thereof
BRPI0815578B8 (pt) Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer)
PE20121393A1 (es) Analogo peptidico de oxintomodulina
JP2014534202A5 (es)
BRPI0905725B8 (pt) vacina e embalagem farmacêutica
AR092897A1 (es) Composiciones inmunogenicas
CL2011001993A1 (es) Composicion inmunogenica que comprende al menos un antigeno del virus del dengue inactivado y un adyuvante sin aluminio; metodo de produccion; y su uso para prevenir, mejorar o tratar una enfermedad productiva por el virus del dengue en un sujeto.
EA201290956A1 (ru) Вакцина против вич
AR079941A2 (es) Organismos clostridium atenuados recombinados y vacuna
ES2531115T3 (es) Combinaciones de clados de RrgB neumocócicos
JP2014521605A5 (es)
AR094291A1 (es) Formulacion inyectable de liberacion prolongada que comprende tolvaptan opticamente activo, y un procedimiento para producirla
WO2011053789A3 (en) Pharmaceutical composition and methods to enhance cytotoxic t-cell recognition and maintain t-cell memory against a pathogenic disease
AR080621A1 (es) Uso de una fuente de l3 y/o l5 como vacuna o como diagnostico para una enfermedad parasitaria
PE20120116A1 (es) Composicion inmunogenica multicomponente para la prevencion de enfermedad estreptococica beta hemolitica (bhs)
MX2011007108A (es) Incrementadores de angiogenesis generados por derrame cerebral y usos de los mismos.
WO2009072555A1 (ja) 癌ワクチン
CR11537A (es) Vacuna

Legal Events

Date Code Title Description
FA Abandonment or withdrawal